​

Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TEVA Stock Forecast

Teva Pharmaceutical Industries (TEVA) stock forecast, based on 44 Wall Street analysts, predicts a 12-month average price target of $32.67, with a high of $35.00 and a low of $28.00. This represents a 8.25% increase from the last price of $30.18.

$10 $15 $20 $25 $30 $35 High: $35 Avg: $32.67 Low: $28 Last Closed Price: $30.18

TEVA Stock Rating

Teva Pharmaceutical Industries stock's rating consensus is Buy, based on 44 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (45.45%), 20 Hold (45.45%), 4 Sell (9.09%), and 0 Strong Sell (0.00%).

Buy
Total 44 0 4 20 20 Strong Sell Sell Hold Buy Strong Buy

TEVA Price Target Upside V Benchmarks

TypeNameUpside
StockTeva Pharmaceutical Industries8.25%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks20.02%

Price Target Trends

1M3M12M
# Anlaysts235
Avg Price Target$35.00$32.67$30.80
Last Closing Price$30.18$30.18$30.18
Upside/Downside15.97%8.25%2.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25281--11
Nov, 25381--12
Oct, 25371--11
Sep, 25371--11
Aug, 25371--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 08, 2025Barclays$35.00$28.3323.54%15.97%
Dec 04, 2025Scotiabank$35.00$28.4123.20%15.97%
Nov 06, 2025Matt DellatorreGoldman Sachs$28.00$24.4014.75%-7.22%
Dec 18, 2024Ashwani VermaUBS$28.00$21.2032.08%-7.22%
Dec 18, 2024Balaji PrasadBarclays$28.00$21.2032.08%-7.22%
Oct 23, 2024Balaji PrasadBarclays$25.00$18.3836.02%-17.16%
Oct 01, 2024Jason GerberryBank of America Securities$22.00$17.7523.94%-27.10%
Sep 03, 2024Ashwani VermaUBS$26.00$18.4341.07%-13.85%
Aug 28, 2024David AmsellemPiper Sandler$23.00$18.6223.52%-23.79%
Aug 01, 2024Balaji PrasadBarclays$22.00$17.4326.22%-27.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 08, 2025BarclaysOverweightOverweightinitialise
Dec 08, 2025Goldman SachsBuyBuyhold
Dec 04, 2025ScotiabankOutperforminitialise
Nov 06, 2025Goldman SachsBuyBuyhold
Sep 24, 2025UBSBuyBuyhold
Dec 18, 2024UBSBuyBuyhold
Dec 18, 2024BarclaysOverweightOverweighthold
Dec 03, 2024Bank of America SecuritiesBuyBuyhold
Oct 23, 2024BarclaysOverweightOverweighthold
Oct 01, 2024Bank of America SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-3.64$0.38$-2.12$-0.50$-1.45---
Avg Forecast$2.51$2.54$2.52$2.32$2.48$2.73$2.97$2.99
High Forecast$2.57$2.60$2.61$2.41$2.53$2.95$3.29$3.10
Low Forecast$2.44$2.47$2.44$2.28$2.44$2.57$2.58$2.86
Surprise %-245.02%-85.04%-184.13%-121.55%-158.47%---

Revenue Forecast

$15B $15B $16B $17B $18B $19B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$16.66B$15.88B$14.93B$15.85B$16.54B---
Avg Forecast$16.59B$16.07B$14.95B$15.39B$16.45B$17.05B$17.49B$16.94B
High Forecast$16.89B$16.36B$15.37B$15.44B$16.52B$17.53B$18.34B$17.41B
Low Forecast$16.26B$15.74B$14.58B$15.29B$16.41B$16.62B$16.63B$16.48B
Surprise %0.38%-1.18%-0.18%2.99%0.60%---

Net Income Forecast

$-5B $-3B $-1B $400M $2B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-3.99B$417.00M$-2.35B$-559.00M$-1.64B---
Avg Forecast$-4.03B$441.15M$406.30M$-559.00M$2.86B$3.18B$3.37B$3.43B
High Forecast$-3.09B$589.34M$553.53M$-356.45M$2.91B$3.40B$3.78B$3.57B
Low Forecast$-4.96B$292.95M$259.08M$-761.55M$2.80B$2.95B$2.97B$3.28B
Surprise %-0.92%-5.47%-679.12%--157.41%---

TEVA Forecast FAQ

Is Teva Pharmaceutical Industries stock a buy?

Teva Pharmaceutical Industries stock has a consensus rating of Buy, based on 44 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 20 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Teva Pharmaceutical Industries is a favorable investment for most analysts.

What is Teva Pharmaceutical Industries's price target?

Teva Pharmaceutical Industries's price target, set by 44 Wall Street analysts, averages $32.67 over the next 12 months. The price target range spans from $28 at the low end to $35 at the high end, suggesting a potential 8.25% change from the previous closing price of $30.18.

How does Teva Pharmaceutical Industries stock forecast compare to its benchmarks?

Teva Pharmaceutical Industries's stock forecast shows a 8.25% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (20.02%).

What is the breakdown of analyst ratings for Teva Pharmaceutical Industries over the past three months?

  • December 2025: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is Teva Pharmaceutical Industries’s EPS forecast?

Teva Pharmaceutical Industries's average annual EPS forecast for its fiscal year ending in December 2025 is $2.73, marking a -288.28% decrease from the reported $-1.45 in 2024. Estimates for the following years are $2.97 in 2026, and $2.99 in 2027.

What is Teva Pharmaceutical Industries’s revenue forecast?

Teva Pharmaceutical Industries's average annual revenue forecast for its fiscal year ending in December 2025 is $17.05B, reflecting a 3.09% increase from the reported $16.54B in 2024. The forecast for 2026 is $17.49B, and $16.94B for 2027.

What is Teva Pharmaceutical Industries’s net income forecast?

Teva Pharmaceutical Industries's net income forecast for the fiscal year ending in December 2025 stands at $3.18B, representing a -293.72% decrease from the reported $-1.639B in 2024. Projections indicate $3.37B in 2026, and $3.43B in 2027.